Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Big Pharma certainly don't need to see a completed P3 double blind placebo trial before they acquire a company .
In fact , most deals are done in pre clinical or early /mid stage phase .
And currently , those with a completed Phase 2 are commanding the best price tags .
What Faron have is very attractive . That is a fact - not a dream .
https://www.evaluate.com/vantage/articles/insights/ma/following-ma-money-phase-and-therapy-area
exactly - someone has pulled a fast one here .
ipf requirements have been pinned on the cfo's desk for 2 years now .
most shareholders would not have minded a further placing to get bexmab p2 finished .
timo is balls deep , and markku etc are also heavily invested .
yes dilution needs to be kept to minimum - but the havoc caused today outweighed any placing side effects .
i think they may have been ambushed with this - caught off guard somehow - who knows .
the solution to todays problem is simple - but the problem was created to cause this 'default' news - like faron were going bust or something . the company haven't made a penny yet - they are always bust - thats how small biotechs operate .
the fact that this has happened just as our breakthrough therapy is in the final stages of getting approval ( 1 year away is miscroseconds in the pharma business ) - and potential suitors are in intensive talks - is no coincidence .
lets see what markku comes back with .
sisu is in their blood - they've had worse chucked at them .
hold tight . i'm ****ed off , but i hope others here can see that this is a hurdle that can be overcome .
I just don't understand how this could have not been avoided ?
We've lost about £65 million quid off the Mcap today , because they were £1.5m short in the kitty .
I think they have been royally tucked up here .
Good news is that they will get it sorted .
Bad news is we have to endure this sort of caper .
Ok , it may all end well , but when they ( and I don't necessarily mean Faron) pull these kind of stunts , it just reeks of corruption .
As I understand Faron are meant to have 6m euros on hand and a 3 month runway to meet the IPF requirements .
So they have 4.3m on hand .
Surely this could be rectified pretty quickly .
I was expecting a placing within weeks anyway .
Someone has either dropped a huge b*llock here , or they are being targeted / played .
Markuu isn't daft , and Timo would be on hand in a an instant if needed .
This has been orchestrated , and I don't think Markku is to blame ( unless I'm proved wrong)
Yes someone is either looking to make a killing or force their hand into a terribly low priced funding package
No doubt weak hands will cause some havoc on the Nas - but I don't think Timo or big investors will let Faron get stuck in some kind of funding catch 22 for long .
I expect a placing will arrive shortly with the usual suspects taking part .
Faron won't be rushed or have their hand forced - but they have been caught short here somehow .
IPF have been bad news - they screwed the price down sub £2 for the last renegotiation , and have been a pain ever since .
Two reasons perhaps .
1.) A deal with a Big Pharma was being finalized - to the point at which IPF criteria would be met . However it crept past deadline or was stalled on purpose to create this mess .
2.)Someone in accounts needs firing .
Looks like Nasdaq may be coming back on line -
Looks like IPF have stuck a spanner in the works again - no doubt in order to renegotiate the deal to their advantage .
But how did our CFO not see this coming ?
Sound a bit underhand to me .
Surely a quick £5m placing could have been rustled up ( and no doubt now will be at a lower price )
AIM still trading - but NASDAQ still suspended ?
Great . Nicely orchestrated .
Trading in the shares of Faron Pharmaceuticals Ltd. was suspended on the Nasdaq
First North Growth Market Finland today at 9:39 EET. The company will publish
an announcement later.
Yes slightly less painful to look at now we are back in the 40's .
Still holding all my shares after that shake out - would have been nice to have had some more in the 30's , but my hands were still sore after catching that falling knife last week .
The old phrase of time in the market and timing the market certainly ring true here .
Onwards and Upwards .
Https://www.sigridjuselius.fi/en/news/top-level-teamwork-changing-the-treatment-of-cancer/
An effective drug is the greatest possible reward
The greatest idea in Jalkanen’s research was found more than twenty years ago when, contrary to the prevailing notion, she refused to believe that the lymphatic system consists of just passive channels. Research proved her suspicion right: the lymphatic system is central for the spread of cancer. In this context, the harmful CLEVER-1 molecule was found.
“CLEVER-1 is a molecule suppressing lymphocytes fighting cancer. We started wondering whether the activity of the harmful molecule could be inhibited. Would we thus be able to prevent cancer from spreading?”
During the long research and drug development process, group members have changed but the joint aim prevails. The extensive “scientific family” is now achieving a reward that makes its work input worthwhile.
“The drug has by now been tested on 250 patients. It would appear to be safe and actually be able to limit the spread of cancer. This is the greatest possible reward for a person who has worked on the research for the whole of their career.”
Yes he was on fire again - so much info not enough time .
Sounds like he is in full salesman mode again this year .
$50 billion - that's about £700 a share , or a 250x bagger .
That'll do .
And there's me thinking £70 would be nice .
Just so long as we don't keep bringing that up like we did about SSV every 6 months when it doesn't happen lol .
Anyway - looks like the recent amazing data he's getting is making his work easier as he goes around talking to interested parties , and competitors even ( as he mentioned) .
p.s as I mentioned before , I've seen two prospective new names for Bex , both quite good and certainly easier to pronounce .
Well I seem to have called the bottom incorrectly about 5 times so far this week .
At least I'm up on todays purchase lol .
I remember a few years ago buying NCYT at 95p , it then promptly sank to 65p .
Good job I didn't panic and sell , because it bounced around then shot to 3,4 ,5 ,8 and then about a tenner .
Mind you I didn't sell at £10 either , but it shows how you have to be in it to win it .
I know we are in different world now , but I still see Destiny as having that kind of potential with their products .
Either there are some very impatient share holders here , or its being maneuvered down . Either way I had another chomp at 48p .
Its getting into silly Mcap territory again for what Dest has in the pipeline .
Yes these small cap pharma shares can be volatile . I added again this morning . Hindsight etc . But at 50m Mcap - any deal that CT comes up with will rerate this share significantly .
The company are doing all the right things . I know the RNS's could be more fruity , but that's a dangerous road to go down sometimes as it puts more expectation on imminent success. 99% of Pharma RNS's are of the ' jam tomorrow' variety .
You don't put multi million deals together within your first few months as CEO unless you are some kind of magician .
So happy to ignore the SP in the short term , top up when possible , and wait for further news .
Well I got my average down thanks to somebody .
Cant beat it when you get positive news , and then they give buyers a massive discount on the same day .
Great update .
The platform looks to be a gaining even more value .
DFI is a huge problem .
He's obviously very capable , but even I have to admit that in the interviews , anyone without a good grounding in the subject will quickly get lost . In these matters of complicated clinical science , if you lose one or two words in a sentence , you are left clueless . I've personally had to replay videos , and even after 5 attempts am still none the wiser sometimes lol .
It's all coming together , and I understand his passion for the science , but when you are talking on Proactive investors , your audience is not Tefal heads in big pharma ,its people like us , who are generally more interested in whether the company can make them money rather than win the Nobel prize .
I hope they do both . The bottom line is , when approval gets close , or a Partner appears - the numbers will do the talking .
It was definitely on the 25th.
https://x.com/FaronPharm/status/1747917545674268699?s=20
But Proactive had also put the 27th up on their site - which can't be right ( Saturday)